Teva CSO Dr. Michael Hayden: We are disappointed with these results.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and OncoGenex Pharmaceuticals Inc. (Nasdaq: OGXI) today announced the results from the Phase III Synergy clinical trial to evaluate the combination of custirsen and standard first-line docetaxel/prednisone therapy in comparison with docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer (CRPC). The trial failed to meet its primary endpoint.
The trial's survival results indicate that the addition of custirsen to docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic CRPC, compared with docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively).
“We are disappointed with these results," said Teva president of Global R&D and chief scientific officer Dr. Michael Hayden. "Addressing treatment resistance is critical in the fight against cancer. We are working with OncoGenex to more fully understand these data."
Published by Globes [online], Israel business news - www.globes-online.com - on April 28, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014